Bickell NA, et al. - Researchers investigated if secondary cytoreductive surgery vs other treatments offers improved overall survival in patients with first recurrence of ovarian cancer. Survival assessment was carried out using Surveillance, Epidemiology and End Results-Medicare data for advanced stage ovarian cancer cases. Overall, 35,995 women with ovarian cancer aged 66 years and older were analyzed, of whom, 3,439 underwent optimal primary debulking surgery with 6 cycles of chemotherapy, and 2,038 experienced a remission. An increase in survival by 1.3 years was achieved with secondary surgery with chemotherapy as the treatment strategy for recurrent ovarian cancer vs chemotherapy alone.